BE2013C023I2 - - Google Patents

Download PDF

Info

Publication number: BE2013C023I2
Authority: BE; Belgium
Prior art keywords: glycopyrrolate; dry powder; formulation; copd; excipient
Prior art date: 2000-04-07

Application number

BE2013C023C

Other languages

English (en)

Original Assignee

Heptares Therapeutics Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-07

Filing date

2013-03-26

Publication date

2020-06-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9889490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2013C023(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-03-26 Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd

2020-06-24 Publication of BE2013C023I2 publication Critical patent/BE2013C023I2/fr

Links

VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 abstract 2
238000009472 formulation Methods 0.000 abstract 2
229940015042 glycopyrrolate Drugs 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
239000000843 powder Substances 0.000 abstract 2
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000000546 pharmaceutical excipient Substances 0.000 abstract 1
230000000144 pharmacologic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Emergency Medicine (AREA)
Otolaryngology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Detergent Compositions (AREA)
Saccharide Compounds (AREA)
Steroid Compounds (AREA)

BE2013C023C 2000-04-07 2013-03-26 BE2013C023I2 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB0008660.3A GB0008660D0 (en)	2000-04-07	2000-04-07	The treatment of respiratory diseases
PCT/GB2001/001606 WO2001076575A2 (fr)	2000-04-07	2001-04-09	Traitement de troubles respiratoires
EP01966751.8A EP1267866B2 (fr)	2000-04-07	2001-04-09	Traitement de troubles respiratoires

Publications (1)

Publication Number	Publication Date
BE2013C023I2 true BE2013C023I2 (fr)	2020-06-24

Family

ID=9889490

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BE2013C023C BE2013C023I2 (fr)	2000-04-07	2013-03-26

Country Status (25)

Country	Link
US (3)	US7229607B2 (fr)
EP (3)	EP1449528B1 (fr)
JP (1)	JP5042426B2 (fr)
CN (3)	CN1292745C (fr)
AT (1)	ATE330585T2 (fr)
AU (2)	AU2004242450B2 (fr)
BE (1)	BE2013C023I2 (fr)
BR (1)	BR0109875A (fr)
CA (1)	CA2405705C (fr)
CY (1)	CY1105120T1 (fr)
DE (1)	DE60120936T3 (fr)
DK (1)	DK1267866T4 (fr)
ES (2)	ES2266242T5 (fr)
GB (1)	GB0008660D0 (fr)
HK (1)	HK1050846B (fr)
HU (2)	HU230958B1 (fr)
IL (2)	IL151791A0 (fr)
LU (2)	LU92166I2 (fr)
MX (1)	MXPA02009718A (fr)
NO (3)	NO336142B1 (fr)
NZ (2)	NZ535284A (fr)
PL (1)	PL364024A1 (fr)
PT (1)	PT1267866E (fr)
WO (1)	WO2001076575A2 (fr)
ZA (1)	ZA200207420B (fr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0008660D0 (en) *	2000-04-07	2000-05-31	Arakis Ltd	The treatment of respiratory diseases
US8580306B2 (en)	2000-11-30	2013-11-12	Vectura Limited	Particles for use in a pharmaceutical composition
EP2283817B1 (fr)	2000-11-30	2016-05-18	Vectura Limited	Procédé de préparation de particules destinées à être utilisées dans une composition pharmaceutique
US20050130990A1 (en) *	2001-03-23	2005-06-16	Universite Laval	Nicotinic receptor agonists for the treatment of inflammatory diseases
CA2341952A1 (fr)	2001-03-23	2002-09-23	Universite Laval	Agonistes du recepteur de la nicotine pour le traitement des maladies pulmonaires inflammatoires
WO2002094321A1 (fr)	2001-05-23	2002-11-28	Tanabe Seiyaku Co., Ltd.	Compositions favorisant la guérison d'une fracture osseuse
KR20040007583A (ko)	2001-05-23	2004-01-24	다나베 세이야꾸 가부시키가이샤	연골 질환의 재생치료용 조성물
ME00077B (fr) *	2002-03-01	2010-06-10	Chiesi Farm Spa	Preparation superfine de formoterol
US8039459B2 (en)	2004-07-15	2011-10-18	Universite Laval	Nicotinic receptor agonists for the treatment of inflammatory diseases
US8557804B2 (en)	2002-03-25	2013-10-15	Universite Laval	Nicotinic receptor agonists for the treatment of inflammatory diseases
US20040121003A1 (en) *	2002-12-19	2004-06-24	Acusphere, Inc.	Methods for making pharmaceutical formulations comprising deagglomerated microparticles
AU2004263900A1 (en) *	2003-08-08	2005-02-17	Arriva Pharmaceuticals, Inc.	Methods of protein production in yeast
GB0327723D0 (en) *	2003-09-15	2003-12-31	Vectura Ltd	Pharmaceutical compositions
PT1684719E (pt) *	2003-11-14	2012-02-03	Baxter Int	Composições de alfa-1-antitripsina e métodos de tratamento utilizando estas composições
ES2413011T3 (es)	2004-02-06	2013-07-15	Meda Pharma Gmbh & Co. Kg	Combinación de anticolinérgicos y glucocorticoides para el tratamiento a largo plazo de asma y EPOC
AU2005210086A1 (en) *	2004-02-06	2005-08-18	Meda Pharma Gmbh & Co. Kg	Treatment of rhinitis with anticholinergics alone in combination with antihistamines phosphodiesterase 4 inhibitors, or corticosteroids
CA2550848C (fr) *	2004-02-06	2013-02-26	Meda Pharma Gmbh & Co. Kg	Combinaison d'anticholinergiques et d'inhibiteurs de phosphodiesterase type 4 pour le traitement de maladies respiratoires
CA2550841C (fr) *	2004-02-06	2012-10-02	Meda Pharma Gmbh & Co. Kg	Nouvelle combinaison d'anticholinergique et de beta-mimetiques pour le traitement de maladies respiratoires
JP2007524698A (ja) *	2004-02-27	2007-08-30	アルタナ　ファルマ　アクチエンゲゼルシャフト	シクレソニドとグリコピロニウムとの組合せ物
US7914771B2 (en) *	2004-03-09	2011-03-29	Arriva Pharmaceuticals, Inc.	Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
GB0409703D0 (en)	2004-04-30	2004-06-02	Vectura Ltd	Pharmaceutical compositions
GB0410398D0 (en) *	2004-05-10	2004-06-16	Arakis Ltd	The treatment of respiratory disease
GB0410399D0 (en) *	2004-05-10	2004-06-16	Arakis Ltd	The treatment of respiratory disease
GB0411056D0 (en)	2004-05-18	2004-06-23	Novartis Ag	Organic compounds
EP1763344A1 (fr) *	2004-06-29	2007-03-21	Boehringer Ingelheim International GmbH	Medicament pour l'inhalation comprenant un steroide et un anticholinergique
EP1616567A1 (fr) *	2004-07-16	2006-01-18	Boehringer Ingelheim Pharma GmbH & Co.KG	Médicaments comprenant des inhibiteurs de PDE-IV et des sels de glycopyrolate pour l'inhalation
EP1789018A1 (fr)	2004-08-27	2007-05-30	The Dow Chemical Company	Administration amelioree de compositions medicamenteuses pour le traitement d'infections parfois mortelles
US20070105768A1 (en) *	2004-11-10	2007-05-10	Rajiv Nayar	Dry recombinant human alpha 1-antitrypsin formulation
GB0425758D0 (en)	2004-11-23	2004-12-22	Vectura Ltd	Preparation of pharmaceutical compositions
WO2006087919A1 (fr) *	2005-01-28	2006-08-24	Takeda Pharmaceutical Company Limited	Composition finement divisee contenant un substance peu hydrosoluble
SI1863476T1 (sl)	2005-03-16	2016-05-31	Meda Pharma Gmbh & Co. Kg	Kombinacija antiholinergikov in antagonistov receptorja levkotriena za zdravljenje respiratornih bolezni
WO2006100453A1 (fr) *	2005-03-24	2006-09-28	Sosei R & D Ltd.	Sels de glycopyrronium et leur application thérapeutique
WO2007070843A2 (fr) *	2005-12-15	2007-06-21	Acusphere, Inc.	Procédés de préparation de formulations pharmaceutiques à base de particules destinées à une administration orale
PL1971369T3 (pl) *	2005-12-21	2010-01-29	Meda Pharma Gmbh & Co Kg	Połączenie R,R-glikopirolanu, rolipramu i budesonidu dla potrzeb leczenia chorób zapalnych
GB2434098A (en) *	2005-12-23	2007-07-18	Novartis Ag	Process for the preparation of an inhalable dry powder formulation
WO2007109142A2 (fr) *	2006-03-17	2007-09-27	Oregon Health & Science University	Antagonistes du recepteur muscarinique m3 pour le traitement des tumeurs exprimant le recepteur muscarinique m3
GB0613161D0 (en) *	2006-06-30	2006-08-09	Novartis Ag	Organic Compounds
US20100247658A1 (en) *	2007-12-13	2010-09-30	Gerhard Muhrer	Organic compounds
WO2009074666A1 (fr) *	2007-12-13	2009-06-18	Novartis Ag	Composés organiques
US20090215734A1 (en) *	2008-02-26	2009-08-27	Elevation Pharmaceuticals, Inc.	Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
US20100055045A1 (en) *	2008-02-26	2010-03-04	William Gerhart	Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
ES2739352T3 (es)	2009-02-26	2020-01-30	Glaxo Group Ltd	Formulaciones farmacéuticas que comprenden 4-{(1R)-2-[(6-{2-[(2,6-diclorobencil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2-(hidroximetil)fenol
PT2435025T (pt) *	2009-05-29	2016-11-11	Pearl Therapeutics Inc	Administração, por via respiratória, de agentes activos
US8815258B2 (en)	2009-05-29	2014-08-26	Pearl Therapeutics, Inc.	Compositions, methods and systems for respiratory delivery of two or more active agents
GB0921075D0 (en)	2009-12-01	2010-01-13	Glaxo Group Ltd	Novel combination of the therapeutic agents
WO2011076841A2 (fr)	2009-12-23	2011-06-30	Chiesi Farmaceutici S.P.A.	Polythérapie destinée à la bronchopneumopathie chronique obstructive
RU2567040C2 (ru)	2009-12-23	2015-10-27	КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А.	Аэрозольная препаративная форма для лечения по поводу хронического обструктивного легочного заболевания
SG181870A1 (en)	2009-12-23	2012-07-30	Chiesi Farma Spa	Aerosol formulation for copd
HRP20140582T4 (hr)	2009-12-23	2023-06-09	Chiesi Farmaceutici S.P.A.	Kombinacijska terapija za copd
EP4008326A1 (fr)	2010-09-29	2022-06-08	Pulmatrix Operating Company, Inc.	Poudres de cations métalliques monovalentes sèches pour inhalation
JOP20120023B1 (ar) *	2011-02-04	2022-03-14	Novartis Ag	صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
RS58456B1 (sr)	2011-08-01	2019-04-30	Univ Monash	Postupak i formulacije za inhalaciju
US20150136130A1 (en)	2012-02-29	2015-05-21	Pulmatrix, Inc.	Inhalable dry powders
JP6454323B2 (ja)	2013-03-15	2019-01-16	パールセラピューティクス，インコーポレイテッド	粒子状結晶性材料のコンディショニングのための方法及びシステム
KR20150135328A (ko)	2013-04-01	2015-12-02	풀매트릭스 인코퍼레이티드	티오트로피움 건조 분말
US9393202B2 (en) *	2013-04-26	2016-07-19	Chiesi Farmaceutici S.P.A	Particle size reduction of an antimuscarinic compound
WO2015094927A1 (fr) *	2013-12-17	2015-06-25	Merck Sharp & Dohme Corp.	Procédé de broyage de milieux pour la fabrication de composants pharmaceutiques actifs dans des propulseurs
AU2014375301C1 (en)	2013-12-30	2026-02-19	Chiesi Farmaceutici S.P.A.	Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
HRP20260435T1 (hr)	2014-09-09	2026-05-08	Vectura Limited	Formulacija koja sadrži glikopirolat, postupak i uređaj
LT3193835T (lt) *	2014-09-15	2018-06-11	Verona Pharma Plc	Skysta inhaliuojama vaisto forma, apimanti rpl554
MA41378A (fr) *	2015-01-20	2017-11-28	Teva Branded Pharmaceutical Prod R & D Inc	Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol
US20160310410A1 (en)	2015-04-24	2016-10-27	Glenmark Specialty S.A.	Pharmaceutical compositions comprising arformoterol and glycopyrronium
MA43047A (fr) *	2015-06-15	2018-08-08	Qaam Pharmaceuticals Llc	Sels d'acides gras de glycopyrronium et leurs procédés de production
US9925168B2 (en) *	2016-01-22	2018-03-27	Chiesi Farmaceutici S.P.A.	Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
US10098837B2 (en)	2016-07-28	2018-10-16	Chiesi Farmaceutici S.P.A.	Combination therapy for COPD
PH12022551243A1 (en)	2019-12-02	2023-09-11	Chiesi Farm Spa	Stainles steel can for pressurised metered dose inhalers

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3400197A (en)	1965-01-26	1968-09-03	Robins Co Inc A H	Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules
US5376386A (en) *	1990-01-24	1994-12-27	British Technology Group Limited	Aerosol carriers
US5849263A (en) *	1993-03-30	1998-12-15	Charlotte-Mecklenburg Hospital Authority	Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
TW402506B (en) *	1993-06-24	2000-08-21	Astra Ab	Therapeutic preparation for inhalation
DE4425255A1 (de) *	1994-07-16	1996-01-18	Asta Medica Ag	Formulierung zur inhalativen Applikation
SA95160463B1 (ar) *	1994-12-22	2005-10-04	استرا أكتيبولاج	مساحيق للاستنشاق
US5612053A (en) *	1995-04-07	1997-03-18	Edward Mendell Co., Inc.	Controlled release insufflation carrier for medicaments
US5690374A (en) *	1996-04-19	1997-11-25	Nor-Easter Enterprises, Inc.	Shock-absorbing tool handle
US6613795B2 (en) *	1996-11-11	2003-09-02	Christian Noe	Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
SI0937041T1 (en) *	1996-11-11	2003-10-31	Christian R. Noe	Use of a pharmaceutically acceptable salt of (3R,2'R)-3-((Cyclopently-hydroxyphenylacetyl)oxy)-1,1-dimethyl-pyrrolidinium for the preparation of a medicament
DE69732306T2 (de) *	1997-01-16	2006-01-12	Massachusetts Institute Of Technology, Cambridge	Zubereitung von partikelhaltigen arzneimitteln zur inhalation
SE9700133D0 (sv) *	1997-01-20	1997-01-20	Astra Ab	New formulation
US6461591B1 (en) *	1997-02-05	2002-10-08	Jago Research Ag	Medical aerosol formulations
US6495167B2 (en) *	1997-03-20	2002-12-17	Schering Corporation	Preparation of powder agglomerates
NZ509328A (en) *	1998-07-24	2002-11-26	Jago Res A	Medicinal aerosol formulations
ATE234604T1 (de) *	1998-08-04	2003-04-15	Jago Res Ag	Medizinische aerosolformulierungen
CN1150895C (zh) *	1998-11-13	2004-05-26	杰格研究股份公司	用于吸入给药的干粉
US6406745B1 (en) *	1999-06-07	2002-06-18	Nanosphere, Inc.	Methods for coating particles and particles produced thereby
WO2001008681A1 (fr) *	1999-08-02	2001-02-08	First Horizon Pharmaceutical Corporation	Methodes d'administration de compositions de glycopyrrolates
GB0008660D0 (en)	2000-04-07	2000-05-31	Arakis Ltd	The treatment of respiratory diseases
US6758795B2 (en) *	2000-08-22	2004-07-06	Stephen Barber	Adjustable water-fillable exercise weights
GB0029903D0 (en) *	2000-12-07	2001-01-24	Arakis Ltd	Use of anti-muscarinic agents
GB0410398D0 (en) *	2004-05-10	2004-06-16	Arakis Ltd	The treatment of respiratory disease
GB0410399D0 (en) *	2004-05-10	2004-06-16	Arakis Ltd	The treatment of respiratory disease
TWI509631B (zh)	2011-02-25	2015-11-21	漢高智慧財產控股公司	用於電子裝置之可燒結銀薄片黏著劑

2000
- 2000-04-07 GB GBGB0008660.3A patent/GB0008660D0/en not_active Ceased
2001
- 2001-04-09 EP EP04011047.0A patent/EP1449528B1/fr not_active Expired - Lifetime
- 2001-04-09 WO PCT/GB2001/001606 patent/WO2001076575A2/fr not_active Ceased
- 2001-04-09 EP EP10153877A patent/EP2193791A1/fr not_active Withdrawn
- 2001-04-09 DK DK01966751.8T patent/DK1267866T4/en active
- 2001-04-09 PL PL01364024A patent/PL364024A1/xx not_active Application Discontinuation
- 2001-04-09 ES ES01966751.8T patent/ES2266242T5/es not_active Expired - Lifetime
- 2001-04-09 ES ES04011047.0T patent/ES2687751T3/es not_active Expired - Lifetime
- 2001-04-09 JP JP2001574093A patent/JP5042426B2/ja not_active Expired - Lifetime
- 2001-04-09 BR BR0109875-6A patent/BR0109875A/pt not_active Application Discontinuation
- 2001-04-09 CA CA2405705A patent/CA2405705C/fr not_active Expired - Lifetime
- 2001-04-09 CN CNB018075584A patent/CN1292745C/zh not_active Expired - Lifetime
- 2001-04-09 DE DE60120936.2T patent/DE60120936T3/de not_active Expired - Lifetime
- 2001-04-09 PT PT01966751T patent/PT1267866E/pt unknown
- 2001-04-09 EP EP01966751.8A patent/EP1267866B2/fr not_active Expired - Lifetime
- 2001-04-09 CN CNA200510076362XA patent/CN1720995A/zh active Pending
- 2001-04-09 HU HU0301518A patent/HU230958B1/hu active Protection Beyond IP Right Term
- 2001-04-09 NZ NZ535284A patent/NZ535284A/xx not_active IP Right Cessation
- 2001-04-09 NZ NZ521476A patent/NZ521476A/en not_active IP Right Cessation
- 2001-04-09 MX MXPA02009718A patent/MXPA02009718A/es active IP Right Grant
- 2001-04-09 CN CN2007101471670A patent/CN101181263B/zh not_active Expired - Lifetime
- 2001-04-09 IL IL15179101A patent/IL151791A0/xx unknown
- 2001-04-09 HK HK03101991.4A patent/HK1050846B/en unknown
- 2001-04-09 AT AT01966751T patent/ATE330585T2/de active
2002
- 2002-09-16 ZA ZA200207420A patent/ZA200207420B/en unknown
- 2002-09-18 IL IL151791A patent/IL151791A/en active IP Right Grant
- 2002-10-01 NO NO20024708A patent/NO336142B1/no not_active IP Right Cessation
- 2002-10-07 US US10/266,717 patent/US7229607B2/en not_active Expired - Lifetime
2004
- 2004-08-24 US US10/926,196 patent/US7368104B2/en not_active Expired - Lifetime
- 2004-12-22 AU AU2004242450A patent/AU2004242450B2/en not_active Expired
2006
- 2006-07-31 CY CY20061101079T patent/CY1105120T1/el unknown
2008
- 2008-03-14 US US12/048,812 patent/US8029768B2/en not_active Expired - Lifetime
2010
- 2010-02-23 AU AU2010200660A patent/AU2010200660B2/en not_active Expired
2013
- 2013-03-13 LU LU92166C patent/LU92166I2/fr unknown
- 2013-03-26 BE BE2013C023C patent/BE2013C023I2/fr unknown
2014
- 2014-03-07 LU LU92393C patent/LU92393I2/fr unknown
2015
- 2015-11-25 NO NO2015024C patent/NO2015024I1/no not_active IP Right Cessation
- 2015-11-25 NO NO2015025C patent/NO2015025I1/no not_active Application Discontinuation
2019
- 2019-12-23 HU HUS1900056C patent/HUS1900056I1/hu unknown

Also Published As

Publication number	Publication date
MXPA02009718A (es)	2003-05-27
US8029768B2 (en)	2011-10-04
DK1267866T3 (da)	2006-10-23
WO2001076575A2 (fr)	2001-10-18
AU2010200660B2 (en)	2012-04-19
PL364024A1 (en)	2004-11-29
US20050019271A1 (en)	2005-01-27
HUP0301518A2 (hu)	2003-08-28
IL151791A (en)	2015-05-31
ES2687751T3 (es)	2018-10-29
HUS1900056I1 (hu)	2020-02-28
AU2004242450A1 (en)	2005-01-20
JP5042426B2 (ja)	2012-10-03
US20030068280A1 (en)	2003-04-10
LU92166I2 (fr)	2014-03-13
EP2193791A1 (fr)	2010-06-09
DK1267866T4 (en)	2016-10-03
EP1267866B2 (fr)	2016-07-20
DE60120936D1 (de)	2006-08-03
ES2266242T5 (es)	2016-10-04
HK1050846A1 (en)	2003-07-11
CN1422154A (zh)	2003-06-04
CA2405705C (fr)	2011-06-07
US7368104B2 (en)	2008-05-06
NO20024708L (no)	2002-10-24
IL151791A0 (en)	2003-04-10
CA2405705A1 (fr)	2001-10-18
DE60120936T2 (de)	2006-11-02
EP1449528A1 (fr)	2004-08-25
BR0109875A (pt)	2004-07-20
NO336142B1 (no)	2015-05-26
GB0008660D0 (en)	2000-05-31
AU8930601A (en)	2001-10-23
ATE330585T2 (de)	2006-07-15
AU776913B2 (en)	2004-09-23
CY1105120T1 (el)	2010-03-03
WO2001076575A3 (fr)	2002-03-28
LU92393I2 (fr)	2015-11-02
NZ535284A (en)	2006-04-28
PT1267866E (pt)	2006-10-31
CN101181263A (zh)	2008-05-21
DE60120936T3 (de)	2016-11-17
EP1267866B1 (fr)	2006-06-21
EP1267866A2 (fr)	2003-01-02
NO2015024I2 (no)	2015-11-25
NZ521476A (en)	2004-10-29
CN1720995A (zh)	2006-01-18
NO2015025I1 (no)	2015-12-07
HK1050846B (en)	2007-01-26
JP2003530344A (ja)	2003-10-14
AU2004242450B2 (en)	2010-06-03
US7229607B2 (en)	2007-06-12
US20080220073A1 (en)	2008-09-11
HU230958B1 (hu)	2019-06-28
EP1449528B1 (fr)	2018-08-08
NO2015024I1 (no)	2015-11-25
CN101181263B (zh)	2011-07-06
NO20024708D0 (no)	2002-10-01
CN1292745C (zh)	2007-01-03
ZA200207420B (en)	2003-09-16
ES2266242T3 (es)	2007-03-01
AU2010200660A1 (en)	2010-03-11

Publication	Publication Date	Title
HUS1900056I1 (hu)	2020-02-28	Légzési rendellenességek kezelésére alkalmas, glikopirrolát tartalmú száraz porkészítményt tartalmazó inhaláló készülék és alkalmazása
MXPA02011311A (es)	2003-04-25	Composicion novedosa.
IL167900A (en)	2013-06-27	Use of betamimetics to prepare a medical preparation for the treatment of chronic obstructive pulmonary disease
IL187438A0 (en)	2008-02-09	Pyrrolopyridine derivatives and pharmaceutical compositions containing the same
WO2002042462A3 (fr)	2003-06-19	Agents therapeutiques et methodes d'utilisation de ces agents therapeutiques pour traiter une maladie amyloidogenique
IL219397A0 (en)	2012-06-28	Compounds for the treatment of metabolic disorders, methods of preparing same, and pharmaceutical compositions containing same
YU92501A (sh)	2004-09-03	Levodop/karbidop/entakapon farmaceutski preparat
HUP0303398A3 (en)	2010-03-29	1,2-dihydropyridine compounds, process for preparation of the same and use thereof and pharmaceutical compositions containing the same
YU71901A (sh)	2005-07-19	NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
IL219785A0 (en)	2012-06-28	Process for preparing a pharmaceutical composition containing an active ingredient and a micronised carrier/diluent
HUP0401086A3 (en)	2011-07-28	4 (phenyl-piperazinyl-methyl) benzamide derivatives and their use for preparation of pharmaceutical compositions for the treatment of pain, anxiety or gastrointestinal disorders and process for preparation the compounds
IL188942A0 (en)	2008-04-13	Benzimidazole derivatives and pharmaceutical compositions containing the same
WO2003087049A3 (fr)	2004-02-05	Combinaisons de produits pharmaceutiques contenant des composes heterocycliques et un nouvel anticholinergique
MY148125A (en)	2013-02-28	Compounds
HUP0102388A3 (en)	2004-11-29	Use of diazepinoindole derivatives for the preparation of pharmaceutical composition treating chronic obstructive pulmonary disease
AP2002002496A0 (en)	2002-06-30	Method and compositions for treating pulmonary diseases.
HUP0204391A3 (en)	2005-03-29	The use of mirtazapine for the preparation of pharmaceutical composition suitable for the treatment of sleep disorders
EP1390012A4 (fr)	2009-10-28	Nouvelles methodes et compositions d'administration de macromolecules aux voies respiratoires ou via celles-ci
HUP0204258A3 (en)	2005-03-29	Use of vitamin d-derivatives for preparation of pharmaceutical compositions useful in the treatment of osteoporosis and related bone disorders, as well as novel vitamin d3-derivatives
WO2002044128A3 (fr)	2003-03-13	Analogues de salicylate utilises en tant qu'antagonistes d'interleukine-4
HUP0002154A3 (en)	2002-06-28	Use of famotidine for the preparation of pharmaceutical compositions treating depression or symptoms related with depression
MY131159A (en)	2007-07-31	New pharmaceutical compositions containing epinastine and pseudoephedrine
WO2004089969A3 (fr)	2004-12-16	Composes contenant du cholesterol et leur utilisation comme immunogenes contre borrelia burgdorferi
EE200200528A (et)	2004-04-15	2-fenüülpüran-4-ooni derivaat, meetod selle valmistamiseks, seda sisaldav farmatseutiline kompositsioon ning ühendi ja kompositsiooni raviotstarbeline kasutamine
CA2430592A1 (fr)	2002-06-27	Nouvelles compositions medicamenteuses a base d'anticholinergiques et d'agonistes de la dopamine